Ocugen, Inc. (OCGN)

1,3400 -0,0500 (-3,60%) In data: 02:40PM EDT. Mercato aperto.

Ocugen, Inc.

11 Great Valley Parkway
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 65

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Shankar Musunuri M.B.A., Ph.D.	Co-Founder, CEO & Chairman	1,2M	1,26M	1964
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director	56,72k	N/D	1967
Dr. Arun Upadhyay Ph.D.	Chief Scientific Officer and Head of Research & Development	N/D	N/D	1983
John Kouch J.D.	General Counsel	N/D	N/D	N/D
Mr. Michael Shine M.B.A.	Senior Vice President of Commercial	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Ocugen, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.